

**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

**SECTION 1. IDENTIFICATION**

Product name : Mometasone Dry Powder Inhaler

**Manufacturer or supplier's details**

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road  
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

Reproductive toxicity : Category 1B

Specific target organ  
systemic toxicity - repeated  
exposure (Inhalation) : Category 2 (Immune system, Liver, Kidney, Skin)

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.  
H360Df May damage the unborn child. Suspected of damaging fertility.  
H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Precautionary Statements : **Prevention:**



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Hazardous ingredients**

Chemical name	CAS-No.	Concentration (% w/w)
Mometasone	83919-23-7	$\geq 10$ - $< 20$

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage the unborn child. Suspected of damaging fertility. May cause damage to organs through prolonged or repeated exposure if inhaled.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	: Treat symptomatically and supportively.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice.  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Organic peroxides  
Explosives  
Gases

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Ingredients	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
-------------	---------	------------------------	----------------------------------	-------



## Mometasone Dry Powder Inhaler

Version 2.3      Revision Date: 05/03/2017      SDS Number: 437334-00005      Date of last issue: 11/07/2016  
 Date of first issue: 01/28/2016

		exposure)	concentration	
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Merck
	Further information: Skin			
		Wipe limit	10 µg/100 cm <sup>2</sup>	Merck

**Engineering measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**  
**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Color	:	white
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Ingredients:****Mometasone:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.  LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Ingredients:****Mometasone:**

Species: Rabbit

Result: No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Ingredients:****Mometasone:**

Species: Rabbit

Result: No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Ingredients:****Mometasone:**

Test Type: Maximization Test

Routes of exposure: Dermal

Species: Guinea pig

Assessment: Does not cause skin sensitization.

Result: negative

Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

**Germ cell mutagenicity**

Not classified based on available information.

**Ingredients:****Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

: Test Type: Chromosomal aberration  
Species: Chinese hamster lung cells  
Result: negative



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

- |  |  |
|--|--|
|  | : Test Type: Chromosomal aberration<br>Species: Chinese hamster ovary cells<br>Result: positive          |
|  | : Test Type: Mouse Lymphoma<br>Result: negative  |
| Genotoxicity in vivo                   | : Test Type: Micronucleus test<br>Species: Mouse<br>Application Route: Oral<br>Result: negative          |
|  | Test Type: Chromosomal aberration<br>Species: Rat<br>Cell type: Bone marrow<br>Result: negative          |
|  | Test Type: unscheduled DNA synthesis assay<br>Species: Rat<br>Cell type: Liver cells<br>Result: negative |
| Germ cell mutagenicity -<br>Assessment | : Weight of evidence does not support classification as a germ<br>cell mutagen.                          |

**Carcinogenicity**

Not classified based on available information.

**Ingredients:****Mometasone:**

Species: Rat  
Application Route: Inhalation  
Exposure time: 2 Years  
Dose: 0.067 mg/kg body weight  
Result: negative

Species: Mouse  
Application Route: Inhalation  
Exposure time: 19 Months  
Dose: 0.160 mg/kg body weight  
Result: negative

**IARC**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Ingredients:****Mometasone:**

- Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 0.015 mg/kg body weight  
Result: No effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Subcutaneous  
Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight  
Result: Embryotoxic effects., Teratogenicity and developmental toxicity
- Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Dermal  
Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight  
Result: Embryo-fetal toxicity.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight  
Result: Embryo-fetal toxicity., Malformations were observed.
- Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight  
Result: Effects on newborn.
- Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight  
Result: Embryo-fetal toxicity., Malformations were observed.
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT-single exposure**

Not classified based on available information.

**Ingredients:****Mometasone:**

Remarks: Based on available data, the classification criteria are not met.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

**STOT-repeated exposure**

May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

**Ingredients:****Mometasone:**

Routes of exposure: inhalation (dust/mist/fume)

Target Organs: Immune system, Liver, Kidney, Skin

Assessment: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Ingredients:****Mometasone:**

Species: Rat

NOAEL: 0.005 mg/kg

LOAEL: 0.3 mg/kg

Application Route: Oral

Exposure time: 30 d

Target Organs: lymph node, Liver, Adrenal gland, Skin, thymus

Species: Dog

LOAEL: 0.5 mg/kg

Application Route: Oral

Exposure time: 30 d

Target Organs: lymph node, Liver, Adrenal gland, Skin, thymus

Species: Rat

NOAEL: 0.00013 mg/l

Application Route: inhalation (dust/mist/fume)

Exposure time: 90 d

Target Organs: Adrenal gland, Lungs, lymph node, spleen, Bone marrow, Kidney, Liver, thymus

Species: Dog

NOAEL: 0.0005 mg/l

Application Route: inhalation (dust/mist/fume)

Exposure time: 90 d

Target Organs: Adrenal gland, Lungs, lymph node, spleen, Bone marrow, Kidney, thymus, Liver

**Aspiration toxicity**

Not classified based on available information.

**Ingredients:****Mometasone:**

No aspiration toxicity classification

**Experience with human exposure****Ingredients:****Mometasone:**



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information****Ingredients:****Mometasone:**

Remarks: Dermal absorption possible

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Ingredients:****Mometasone:**

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility.  LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility.  EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility.
Toxicity to algae	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

M-Factor (Chronic aquatic toxicity) : 100

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

**Persistence and degradability****Ingredients:****Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

**Bioaccumulative potential****Ingredients:****Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9

**IATA-DGR**

UN/ID No.	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	Miscellaneous
Packing instruction (cargo aircraft)	:	956
Packing instruction (passenger aircraft)	:	956

**IMDG-Code**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

UN/ID/NA number	:	UN 3077
Proper shipping name	:	Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class	:	9
Packing group	:	III
Labels	:	CLASS 9
ERG Code	:	171
Marine pollutant	:	yes(Mometasone)
Remarks	:	Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

(IATA) or IMO.

---

**SECTION 15. REGULATORY INFORMATION****EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Fire Hazard  
Chronic Health Hazard

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations****Pennsylvania Right To Know**

Lactose	63-42-3
Mometasone	83919-23-7

**California Prop. 65**

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined




## Mometasone Dry Powder Inhaler

Version  
2.3Revision Date:  
05/03/2017SDS Number:  
437334-00005Date of last issue: 11/07/2016  
Date of first issue: 01/28/2016

## SECTION 16. OTHER INFORMATION

## Further information

## NFPA:



## HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

## Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -



**Mometasone Dry Powder Inhaler**

Version	Revision Date:	SDS Number:	Date of last issue: 11/07/2016
2.3	05/03/2017	437334-00005	Date of first issue: 01/28/2016

---

United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/03/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8